NCT00373646View on ClinicalTrials.gov

Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
MALT Lymphoma
Interventions
DRUG

Thalidomide, Pharmion

200 mg p.o. daily

Trial Locations (1)

1090

Department of Internal Medicine I, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00373646 - Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients | Biotech Hunter | Biotech Hunter